NVO
Novo Nordisk A/S
NVO
Novo Nordisk A/S
Canada's new retaliatory tariffs on $20B of U.S. goods escalate trade tensions, impacting North American manufacturers and supply chains. ASML secures commitments from Samsung, TSMC, and Intel for Hig
BioAge Labs remains a buy despite a >40% stock drop, as the recent sell-off appears overblown given competitive Phase 1 data for BGE-102. BGE-102, a best-in-class NLRP3 inhibitor, achieved up to 98% I
Novo Nordisk A/S NYSE: NVO reported second-quarter adjusted sales growth of 7% at constant exchange rates, supported by GLP-1 volume growth across its obesity and diabetes franchises, while lower real
Both Eli Lilly and Novo Nordisk beat second-quarter estimates and raised their full-year outlooks. But while investors cheered Lilly's results, they punished Novo a day earlier – underscoring a growin
SpaceX (SPCX) will deliver its first public earnings report, with focus on Starlink growth, Starship timeline, and capital spending. SPCX shares have fallen over 50% from peak and are 20% below the IP
Novo Resources Corp (TSX:NVO, OTCQX:NSRPF, ASX:NVO, FRA:1NOR) earlier this week outlined plans for a 2,700-metre reverse circulation drilling program at the...
Wall Street navigated a turbulent week as investors digested the Federal Reserve's latest interest rate decision, a barrage of Big Tech earnings , and renewed geopolitical tensions.
Novo Nordisk shares dive 9% after heart medicine fails trial
The S&P/ASX Small Ordinaries Index (XSO) edged 3.7 points, or 0.11%, higher on Wednesday to close at 3,326.50, although the benchmark remains 44.5 points,...
Novo Nordisk (NVO) is rated a Modest Buy with a raised price target of $80, driven by oral Wegovy's rapid market adoption. Oral Wegovy has achieved over 3 million prescriptions in five months, with 80
I initiate Novo Nordisk with a BUY rating and $68 price target, viewing current valuation as an attractive entry point. Oral Wegovy is expanding the treated obesity market, not just cannibalizing inje
Novo Nordisk: Mr. Market Is Pricing In Success, But It's Too Early To Bank On That
Eli Lilly and Company, Abbott Laboratories, AbbVie, Novo Nordisk A/S, Pfizer, Bristol Myers Squibb, and Gilead Sciences are the seven Pharmaceutical stocks to watch today, according to MarketBeat's st
Novo Nordisk remains a Buy, supported by favorable catalysts and a resilient long-term bull case. NVO has surged 41% since my previous coverage, outperforming the benchmark's 18% return. Despite a rec